BATE KENNETH

Director BATE KENNETH sold 16,575 shares (16.6K) at $484.30 avg for $8,027,354.14 ($8.0M) on 2025-11-05, reducing stake by 86.3% to 2,627 shares

Director BATE KENNETH executed 11 separate sales totaling 16,575 shares for $8,027,354.14 on 2025-11-05, reducing his holdings from 19,202 shares to 2,627 shares—an 86.3% reduction. The stock currently trades at $489.26, at its 52-week high, and has gained 12.0% over the last 30 days and 41.5% over 90 days, suggesting strong recent momentum. MDGL is unprofitable (net income of -$114,190,000 on revenue of $287,268,000), which adds context to the magnitude of this director-level divestment. Notably, the insider's prior five trades at MDGL (all on 2025-08-15) showed subsequent 30-day gains of 17.3% to 18.9%, indicating that his earlier sales at that ticker preceded or coincided with continued upside, not downside reversals.

Director BATE KENNETH sells 10,000 shares (79.2% of holdings) for $3,652,008.56 at MDGL, averaging $365.20; prior 5 same-ticker sales all well-timed at 90d.

BATE KENNETH executed 6 separate sales totaling 10,000 shares for $3,652,008.56 on 2025-08-15, reducing his holdings from 12,627 to 2,627 shares and divesting 79.2% of his position. At MDGL specifically, all 5 of his prior open-market sales (conducted on 2025-02-27) proved well-timed at the 90-day mark, with each followed by negative returns ranging from -22.8% to -24.8%. The current transaction occurs with the stock at $369.84, within 1.0% of its 52-week high, after a sharp 27.1% advance over 90 days and 7.2% over 30 days. The company remains unprofitable on a full-year basis with a net loss of $42,281,000.00 against revenue of $212,802,000.00, creating a fundamental backdrop of operational losses despite significant market appreciation. This represents a material departure from his recent holding pattern and echoes his established timing discipline at this ticker, warranting close observation of post-transaction price dynamics.

Director Bate sold 20,000 shares (91.3% of holdings) for $7.1M across 9 transactions on 2025-02-27, leaving 1,912 shares post-sale.

Kenneth Bate, a director at Madrigal Pharmaceuticals, executed 9 separate sales totaling 20,000 shares for $7,128,758.95 on 2025-02-27, reducing his position from 21,912 to 1,912 shares—a 91.3% reduction. The blended average transaction price of $356.44 is near the 52-week high of $355.88, and the stock is now trading 4.1% below that peak at $341.27. Bate's prior sales at this ticker (5 trades on 2024-04-02) all resulted in positive 90-day returns, indicating his prior MDGL sales have historically preceded stock gains—a poorly timed pattern for a seller. The company remains unprofitable, having generated $62.2M in revenue against a net income of -$107.0M in the most recent quarter, adding fundamental context to the near-complete liquidation of his stake.